{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=i-scan&page=22", "query": { "intervention": "i-scan", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 682, "total_pages": 69, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=i-scan&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=i-scan&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T16:23:38.465Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02356159", "title": "Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes", "Hodgkin's Lymphoma", "Non-Hodgkin's Lymphoma", "Acute Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Conditioning chemotherapy", "type": "DRUG" }, { "name": "TMS", "type": "DRUG" }, { "name": "FLAG", "type": "DRUG" }, { "name": "EPOCH-F", "type": "DRUG" }, { "name": "Hematopoietic stem cell transplant", "type": "PROCEDURE" }, { "name": "Palifermin", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Epinephrine", "type": "DRUG" }, { "name": "IV Saline", "type": "OTHER" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "ECHO", "type": "DIAGNOSTIC_TEST" }, { "name": "MUGA", "type": "DIAGNOSTIC_TEST" }, { "name": "DEXA", "type": "DIAGNOSTIC_TEST" }, { "name": "CT chest", "type": "DIAGNOSTIC_TEST" }, { "name": "PET", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "BM aspirate", "type": "PROCEDURE" }, { "name": "BM biopsy", "type": "PROCEDURE" }, { "name": "Lumbar puncture", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2015-09-24", "completion_date": "2025-03-25", "has_results": true, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-10-31T16:23:38.465Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Minneapolis, Minnesota", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02356159" }, { "nct_id": "NCT05687123", "title": "Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Neuroendocrine Tumor", "Pancreatic Neoplasm", "Stage III Pancreatic Neuroendocrine Tumor AJCC v8", "Stage IV Pancreatic Neuroendocrine Tumor AJCC v8", "Unresectable Pancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Sunitinib Malate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2024-08-14", "completion_date": "2026-12-14", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-31T16:23:38.465Z", "location_count": 9, "location_summary": "Duarte, California • Irvine, California • Orange, California + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Shiloh", "state": "Illinois" }, { "city": "City of Saint Peters", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05687123" }, { "nct_id": "NCT05554328", "title": "Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Endometrial Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Selumetinib Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 165, "start_date": "2023-04-25", "completion_date": "2027-10-09", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-31T16:23:38.465Z", "location_count": 292, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 229 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Kingman", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05554328" }, { "nct_id": "NCT00604461", "title": "Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "Carboplatin, Bevacizumab and Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2007-10", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2017-03-23", "last_synced_at": "2026-10-31T16:23:38.465Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00604461" }, { "nct_id": "NCT01320059", "title": "Study of 18F-Fluoro-PEG6-IPQA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "18F-PEG6-IPQA", "type": "DRUG" }, { "name": "Positron emission tomography (PET)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2012-02", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2016-06-27", "last_synced_at": "2026-10-31T16:23:38.465Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01320059" }, { "nct_id": "NCT01017133", "title": "Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "fludeoxyglucose F 18", "type": "RADIATION" }, { "name": "Fluorine F 18 EF5", "type": "RADIATION" }, { "name": "Positron emission tomography", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "PROCEDURE" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2009-05", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2012-09-26", "last_synced_at": "2026-10-31T16:23:38.465Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01017133" }, { "nct_id": "NCT01989585", "title": "Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Malignant Solid Neoplasm", "Metastatic Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Navitoclax", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Trametinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2014-03-24", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-31T16:23:38.465Z", "location_count": 49, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 37 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01989585" }, { "nct_id": "NCT03233555", "title": "Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage I Breast Cancer", "Stage I Colorectal Cancer AJCC v6 and v7", "Stage I Prostate Cancer", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage II Breast Cancer", "Stage II Colorectal Cancer AJCC v7", "Stage II Prostate Cancer", "Stage IIA Breast Cancer", "Stage IIA Colorectal Cancer AJCC v7", "Stage IIA Prostate Cancer", "Stage IIB Breast Cancer", "Stage IIB Colorectal Cancer AJCC v7", "Stage IIB Prostate Cancer", "Stage IIC Colorectal Cancer AJCC v7", "Stage III Colorectal Cancer AJCC v7", "Stage IIIA Colorectal Cancer AJCC v7", "Stage IIIB Colorectal Cancer AJCC v7", "Stage IIIC Colorectal Cancer AJCC v7" ], "interventions": [ { "name": "Informational Intervention", "type": "OTHER" }, { "name": "Internet-Based Intervention", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Telephone-Based Intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 535, "start_date": "2013-09-03", "completion_date": "2022-07-31", "has_results": false, "last_update_posted_date": "2022-08-29", "last_synced_at": "2026-10-31T16:23:38.465Z", "location_count": 2, "location_summary": "New Brunswick, New Jersey • Philadelphia, Pennsylvania", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03233555" }, { "nct_id": "NCT06914999", "title": "Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Head and Neck Squamous Cell Carcinoma", "Hypopharyngeal Squamous Cell Carcinoma", "Laryngeal Squamous Cell Carcinoma", "Oropharyngeal Squamous Cell Carcinoma", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVA Hypopharyngeal Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVB Hypopharyngeal Carcinoma AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Intensity-Modulated Proton Therapy", "type": "PROCEDURE" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Sodium Fluoride F-18", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "RADIATION", "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-12-03", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2025-10-22", "last_synced_at": "2026-10-31T16:23:38.465Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06914999" }, { "nct_id": "NCT02491632", "title": "Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Malignant Neoplasm", "Fatigue", "Metastatic Malignant Neoplasm", "Recurrent Malignant Neoplasm", "Refractory Malignant Neoplasm" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Exercise Intervention", "type": "BEHAVIORAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BEHAVIORAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2015-08-13", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-31T16:23:38.465Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02491632" } ] }